This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.

Many online sellers of compounded GLP-1 receptor agonists may be misleading customers, a cross-sectional study suggested. Out of 79 websites that sold a compounded GLP-1 agent, 11 (13.9%) failed to ...

Pharmaceutical company Novo Nordisk is pursuing legal action against two compounding pharmacies for allegedly offering contaminated copycat versions of the drug semaglutide, found in weight-loss ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of metabolic diseases, offering substantial benefits in glycemic control, weight reduction, cardiovascular ...

Weight loss drug maker Eli Lilly has filed suit against 10 medical spas, wellness clinics and compounding pharmacies over claims they are selling unauthorized versions of the diabetes drug Mounjaro.

Industry Analysis Examines How Cost-Conscious Patients Navigate GLP-1 Options After FDA Oral Semaglutide Approval - Platform Verification Methods, Compounded Medication Regulatory Status, and Third-Pa ...